Biotricity announces new solution for personal heart management with Bioheart

Bioheart comfortably and continuously monitors daily activities and provides advanced heart performance data in a user-friendly format


LAS VEGAS, Jan 11, 2021 (GLOBE NEWSWIRE)Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the upcoming release of Bioheart, a personal heart monitor. Designed for individuals diagnosed with or at risk for cardiovascular disease, Bioheart continuously monitors daily activities, and provides critical information on the user’s heart performance, empowering patients to understand better and manage their heart conditions.

Bioheart availability is targeted for Q3 2021. Biotricity will showcase Bioheart at Pepcom’s Digital Experience during CES 2021 on January 11, 2021. For an advance look at Bioheart, watch this video.

Bioheart is a natural extension to Biotricity’s cardiac diagnostic offering. Today, there is no solution for personal lifestyle management in cardiac diagnostics. Bioheart will fill this gap while enhancing awareness for patients so they can visit their physician and receive a proper diagnosis.

“Cardiovascular disease is the number one killer in the US. Millions of cardiac patients are living with cardiac disease with no insight into their condition,” said Dr. Waqaas Al-Siddiq, founder & CEO, Biotricity Inc. “Bioheart will help cardiac patients to take control of their condition and improve their quality of life.”

Key features of Bioheart include:

  • Dry Lead Technology – Bioheart is one of the only wearable devices that continuously collects ECG (heart) data through dry lead electrodes.
  • Provides Critical Information – Bioheart monitors heart health, respiration, physical activity, and calorie burn in a user-friendly format.
  • Ergonomic Design – Bioheart is designed to maximize patient comfort during regular day-to-day activities through its adjustable chest band.
  • Three-Channel Recording – Bioheart is one of the only consumer wearable that can provide continuous three-channel recording of ECG data. All other known consumer devices are one-channel and lack continuous recording capability.
  • Extended Battery Life – The device can be worn continuously for 48 hours before requiring a one-hour charge, enabling long term continuous data collection.
  • Complementing Data – Individuals can gain further insights by sharing their Bioheart data with health care professionals for lifestyle management.
  • Proven Technology – Bioheart uses the same core ECG technology used in the FDA-cleared Bioflux to diagnose patients.

“We are very excited about the addition of the Bioheart personal heart monitor to our product portfolio and believe it will complement our existing and future product offerings.”, added Dr. Waqaas Al Siddiq.

Bioheart is a personal lifestyle solution for individuals to purchase directly. Bioheart retails for $199 and can be pre-ordered at

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.


Media contacts

Donna Loughlin Michaels

Investor relations:

Biotricity Investor Relations